Supplementary information

# Screening of Hepatocellular Carcinoma via Machine Learning Based on Atmosphere Pressure Glow Discharge Mass Spectrometry 

Jinghan Fan ${ }^{\text {a, } b, ~ X i a o ~ W a n g ~}{ }^{\mathrm{a}, \mathrm{b}}$, Yile $\mathrm{Yu}^{\mathrm{a}, \mathrm{b}}$, Yuze Li ${ }^{\mathrm{c}, *}$, and Zongxiu Nie ${ }^{\mathrm{a}, \mathrm{b}}$ *<br>${ }^{\text {a }}$ Beijing National Laboratory for Molecular Sciences, Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China<br>${ }^{\mathrm{b}}$ University of Chinese Academy of Sciences, Beijing 100049, China<br>${ }^{\text {c }}$ State Key Laboratory of High-efficiency Utilization of Coal and Green Chemical Engineering, College of Chemistry and Chemical Engineering, Ningxia University, Yinchuan 750021, China<br>* Corresponding authors:<br>Zongxiu Nie<br>Beijing National Laboratory for Molecular Sciences, Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences, Beijing<br>100190, China<br>Email: znie@iccas.ac.cn<br>Yuze Li<br>State Key Laboratory of High-efficiency Utilization of Coal and Green Chemical Engineering, College of Chemistry and Chemical Engineering, Ningxia University, Yinchuan<br>750021, China<br>Email: liyuze@nxu.edu.cn


b


Fig. S1 The characteristics of (a) age and (b) gender in HC and HCC cohorts.

Table S1 Summary of 43 HCC patients and 47 HC participants for APGD-MS analysis of urine

| Subject | Age | Sex | Subject | Age | Sex |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HC | 30 | male | HCC | 31 | female |
| HC | 32 | male | HCC | 33 | female |
| HC | 33 | male | HCC | 36 | male |
| HC | 35 | male | HCC | 41 | male |
| HC | 41 | male | HCC | 43 | female |
| HC | 43 | male | HCC | 45 | male |
| HC | 45 | male | HCC | 46 | male |
| HC | 46 | male | HCC | 46 | male |
| HC | 47 | male | HCC | 46 | female |
| HC | 47 | male | HCC | 46 | male |
| HC | 47 | female | HCC | 47 | male |
| HC | 48 | male | HCC | 47 | male |
| HC | 49 | male | HCC | 48 | male |
| HC | 49 | male | HCC | 49 | male |
| HC | 50 | male | HCC | 49 | male |
| HC | 50 | male | HCC | 49 | male |
| HC | 50 | male | HCC | 50 | male |
| HC | 50 | male | HCC | 51 | male |
| HC | 51 | female | HCC | 51 | male |
| HC | 52 | female | HCC | 52 | male |
| HC | 52 | male | HCC | 52 | male |
| HC | 53 | male | HCC | 53 | male |
| HC | 53 | male | HCC | 53 | male |
| HC | 53 | male | HCC | 53 | male |
| HC | 53 | male | HCC | 54 | male |
| HC | 54 | male | HCC | 55 | male |


| HC | 54 | male | HCC | 55 | female |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HC | 55 | male | HCC | 56 | male |
| HC | 55 | male | HCC | 60 | female |
| HC | 56 | male | HCC | 61 | male |
| HC | 57 | male | HCC | 61 | male |
| HC | 58 | male | HCC | 62 | male |
| HC | 58 | male | HCC | 63 | male |
| HC | 60 | male | HCC | 65 | male |
| HC | 60 | male | HCC | 66 | male |
| HC | 61 | male | HCC | 66 | male |
| HC | 63 | male | HCC | 66 | male |
| HC | 63 | female | HCC | 67 | male |
| HC | 65 | male | HCC | 68 | male |
| HC | 66 | male | HCC | 70 | male |
| HC | 67 | male | HCC | 74 | male |
| HC | 68 | female | HCC | 74 | male |
| HC | 69 | male | HCC | 74 | male |
| HC | 71 | female |  |  |  |
| HC | 72 | male |  |  |  |
| HC | 73 | male |  |  |  |
| HC | 75 | male |  |  |  |



Fig. S2 (a) A photograph of the DSI platform. (b) The internal structure of APGD ion source.




Scheme S1 The derivatization reaction of carbonyl compounds with DMED and their possible fragmentation pathways.

b


Fig. S3 Operational processes of (a) general and (b) our derivatization protocols. The processing time were 4-5 hours and 10 minutes respectively.


Fig. S4 The flow chart of data processing procedure.


Fig. S5 Trends of intensity of DMED over time. (a) The trend of relative peak intensity of DMED under different adding volumes and derivatization times. (b) The trend of peak intensity of DMED ( $m / z 89$ ) and its products $(m / z 158,185,187)$ over time under the condition of adding $2.5 \mu \mathrm{~L}$ DMED to $100 \mu \mathrm{~L}$ water.


Fig. S6 The trend of relative peak intensity of (a) 5-aminosalicylic acid, (b) Cysteine and (c) proline under different adding volumes of DMED and derivatization times. The derivatization could be finished within 10 minutes and the sufficient adding volumes of DMED are $0.25,0.5$ and $1.0 \mu \mathrm{~L}$ respectively.

Table S2 Metabolites identified using different protocols by high－resolution MS．

| Metabolites Identified Through Our Protocol |  |  |  |  |  | Metabolites Identified Through General Protocol |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| No． | $m / z$ | Ion Type | CID | Classification | Assignment | No． | $m / z$ | Ion Type | CID | Classification | Assignment |
|  | 89 | $[\mathrm{M}+\mathrm{H}]^{+}$ |  | Label reagent | DMED |  | 89 | $[\mathrm{M}+\mathrm{H}]^{+}$ |  | Label reagent | DMED |
| 1 | 114 | $[\mathrm{M}+\mathrm{H}]^{+}$ |  |  | Creatinine $\dagger$ | 1 | 114 | $[\mathrm{M}+\mathrm{H}]^{+}$ |  |  | Creatinine $\dagger$ |
| 2 | 115 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\mathrm{m} / \mathrm{z}=72$ | Ketone | Acetaldehyde $\dagger$ | 2 | 115 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\mathrm{m} / \mathrm{z}=72$ | Ketone | Acetaldehyde $\dagger$ |
| 3 | 117 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Formic acid $\dagger$ | 3 | 117 | $\left[\mathrm{M}\right.$－${ }^{\text {dMED }+\mathrm{H}]^{+}}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Formic acid $\dagger$ |
| 4 | 121 | $[2 \mathrm{M}+\mathrm{H}]^{+}$ |  |  | Urea（Dimer）$\dagger$ | 4 | 121 | $[2 \mathrm{M}+\mathrm{H}]^{+}$ |  |  | Urea（Dimer）$\dagger$ |
| 5 | 129 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\mathrm{m} / \mathrm{z}=72$ | Ketone | Acetone | 5 | 131 | $\left[\mathrm{M}\right.$－${ }^{\text {DMED }+\mathrm{H}]^{+}}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Acetic acid $\dagger$ |
| 6 | $131$ | $\left.\mathrm{MM}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Acetic acid $\dagger$ | 6 | 132 | $[\mathrm{M}+\mathrm{H}]^{+}$ |  |  | Creatine $\dagger$ |
| 7 | 132 | $[\mathrm{M}+\mathrm{H}]^{+}$ |  |  | Creatine $\dagger$ | 7 | 157 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Crotonic acid $\dagger$ |
| 8 | 145 | $\left[口 M \_D M E D+H\right] ~^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Propionic acid | 8 | 161 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Lactic acid $\dagger$ |
| 9 | 146 | $[\mathrm{M} \text {＿DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Glycine | 9 | 189 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | $\beta$－Hydroxyisovaleric acid |
| 10 | 147 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Glycolic acid | 10 | 193 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Benzoin acid $\dagger$ |
| 11 | 156 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Cyanoacetic acid | 11 | 200 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | L－Pyroglutamic acid $\dagger$ |
| 12 | 157 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Crotonic acid $\dagger$ | 12 | 201 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Heptanoic acid $\dagger$ |
| 13 | 159 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\mathrm{m} / \mathrm{z}=72$ | Ketone | Pyranic acid | 13 | 203 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | L－Ornithine $\dagger$ |
| 14 | 160 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Alanine | 14 | 216 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | N－Isobutyrylglycine |
| 15 | 161 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Lactic acid $\dagger$ | 15 | 223 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | 4－Hydroxyphenylacetic acid |
| 16 | 169 | $\left[口 M \_D M E D+H\right] ~^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | 2，4－Pentadienoic acid | 16 | 227 | $[2 \mathrm{M}+\mathrm{H}]^{+}$ |  |  | Creatinine（dimer）$\dagger$ |
| 17 | 171 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Allylacetic acid | 17 | 229 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | 4－hydroxycyclohexylacetic acid |
| 18 | 173 | $\left[口 M \_D M E D+H\right] ~^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | N－Valeric Acid | 18 | 231 | $[\mathrm{M} \text {＿DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | 3－Methyladipic acid |
| 19 | 175 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Hydroxypyruvic acid | 19 | 237 | $[\mathrm{M} \text {－DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Perillic acid $\dagger$ |


| 20 | 183 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | 2-Furoic acid | 20 | 243 | $[\mathrm{M} \text {-DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Octendioic acid |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 21 | 184 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | 1-pyrroline-5carboxylic acid | 21 | 244 |  | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | N -Acetylglycine |
| 22 | 186 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Proline | 22 | 245 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Arginine $\dagger$ |
| 23 | 188 | $[\mathrm{M} \text { _DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Guanidoacetic acid | 23 | 246 | [M_DMED+H] ${ }^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Indole-3-acetic acid |
| 24 | 192 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Cysteine | 24 | 250 | [M_DMED+H] ${ }^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Hippuric acid $\dagger$ |
| 25 | 193 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Benzoin acid $\dagger$ | 25 | 270 | $[\mathrm{M} \text {-DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Octenoylglycine |
| 26 | 194 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Nicotinic acid | 26 | 271 | $[\mathrm{M} \text {-DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Decenedioic acid |
| 27 | 197 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | 5-Methylfuran-2carboxylic acid | 27 | 272 |  | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Caprylylglycine |
| 28 | 199 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | 3-Heptenioc acid | 28 | 290 | $[\mathrm{M} \text {-DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Pantothenic acid |
| 29 | 200 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | L-Pyroglutamic acid $\dagger$ |  |  |  |  |  |  |
| 30 | 201 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Heptanoic acid $\dagger$ |  |  |  |  |  |  |
| 31 | 202 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Creatine |  |  |  |  |  |  |
| 32 | 203 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | L-Ornithine $\dagger$ |  |  |  |  |  |  |
| 33 | 209 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | 4-Hydroxybenzioc acid |  |  |  |  |  |  |
| 34 | 217 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Glutamine |  |  |  |  |  |  |
| 35 | 224 | $\left[\mathrm{M}\right.$ _DMED+H] ${ }^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | 5-Aminosalicylic acid |  |  |  |  |  |  |
| 36 | 225 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | 2,5-Dihydroxybenzioc acid |  |  |  |  |  |  |
| 37 | 227 | $[2 \mathrm{M}+\mathrm{H}]^{+}$ |  |  | Creatinine (dimer) $\dagger$ |  |  |  |  |  |  |
| 38 | 237 | $[\mathrm{M} \text { _DMED }+\mathrm{H}]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Perillic acid $\dagger$ |  |  |  |  |  |  |
| 39 | 238 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\mathrm{m} / \mathrm{z}=72$ | Ketone | N-Acetyltaurine |  |  |  |  |  |  |
| 40 | 245 | $\left[\mathrm{M}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Arginine $\dagger$ |  |  |  |  |  |  |
| 41 | 250 | $\left[\mathrm{M}\right.$ _DMED+H] ${ }^{+}$ | $\Delta \mathrm{m} / \mathrm{z}=-45$ | Acid | Hippuric acid $\dagger$ |  |  |  |  |  |  |
| $\dagger$ The |  | metab |  |  |  | ntifi |  | 1 |  | both | pro |

Table S3 Detailed information on metabolites only identified in general protocol.

| Compound | Formula | Theoretical $m / z$ | Experimental m/z | Adduct | Delta (ppm) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\beta$-Hydroxyisovaleric acid | $\mathrm{C}_{5} \mathrm{H}_{10} \mathrm{O}_{3}$ | 189.1603 | 189.1608 | $[\mathrm{M} \text { _ DMED }+\mathrm{H}]^{+}$ | 2.6739 |
| N-Isobutyrylglycine | $\mathrm{C}_{6} \mathrm{H}_{11} \mathrm{NO}_{3}$ | 216.1712 | 216.1713 | $[\mathrm{M} \text { - DMED }+\mathrm{H}]^{+}$ | 0.4626 |
| 4-Hydroxyphenylacetic acid | $\mathrm{C}_{8} \mathrm{H}_{8} \mathrm{O}_{3}$ | 223.1446 | 223.1448 | $[\mathrm{M} \text { - DMED }+\mathrm{H}]^{+}$ | 0.8963 |
| 4-hydroxycyclohexylacetic acid | $\mathrm{C}_{8} \mathrm{H}_{14} \mathrm{O}_{3}$ | 229.1916 | 229.1917 | $[\mathrm{M} \text { - DMED }+\mathrm{H}]^{+}$ | 0.4612 |
| 3-Methyladipic acid | $\mathrm{C}_{7} \mathrm{H}_{12} \mathrm{O}_{4}$ | 231.1709 | 231.1709 | $[\mathrm{M} \text { - DMED }+\mathrm{H}]^{+}$ | 0 |
| Octendioic acid | $\mathrm{C}_{8} \mathrm{H}_{12} \mathrm{O}_{4}$ | 243.1709 | 243.1708 | $[\mathrm{M} \text { - DMED }+\mathrm{H}]^{+}$ | 0.2422 |
| N -Acetylglycine | $\mathrm{C}_{4} \mathrm{H}_{7} \mathrm{NO}_{3}$ | 244.2025 | 244.2025 | $[\mathrm{M} \text { - DMED }+\mathrm{H}]^{+}$ | 0 |
| Indole-3-acetic acid | $\mathrm{C}_{10} \mathrm{H}_{9} \mathrm{NO}_{2}$ | 246.1606 | 246.1605 | $\left.\mathrm{MM}_{-} \mathrm{DMED}+\mathrm{H}\right]^{+}$ | 0.4062 |



9-Phenylacridine
Chemical Formula: $\mathrm{C}_{19} \mathrm{H}_{13} \mathrm{~N}$ m/z: 255.1(100.0\%), 256.1(21.07\%), 257.1(2.11\%), 258.1(0.13\%)
b


C


Fig. S7 (a) The structure of 9-phenylacridine. (b) The mass spectrum of 9phenylacridine (saturated aqueous solution) in positive ion mode. (c) The repeatability of 9-PA. $100 \mu \mathrm{~L}$ water was mixed with $10 \mu \mathrm{~L}$ saturated aqueous solution of 9-PA.


Fig. S8 Quantification study of the screening method. (a) The internal calibration curve for relative quantification of creatinine according to the ion intensity ratio of $[\text { creatinine }+\mathrm{H}]^{+}$and $[9-\mathrm{PA}+\mathrm{H}]^{+} .100 \mu \mathrm{~L}$ standard solution of creatinine was mixed with $10 \mu \mathrm{~L}$ saturated aqueous solution of 9-PA. (b) The LOD of creatinine, creatine and arginine. (c) The repeatability heatmap of metabolites relative peak intensities. The similarity can be found from the plot. ( $\mathrm{n}=30$ ) (d) The RSD of some typical metabolites. There were all within the acceptable range.


Fig. S9 Heatmap of 90 urine samples with 270 mass spectra.


Fig. S10 The OPLS-DA plot of HCC and HC cohorts.


Fig. S11 Screening results of machine learning models using 11 potential urinary biomarkers of HCC as features. (a) Evaluation results of 5 different models. (b) ROC curves of 5 different models. (c) Confusion matric of the test cohort.

